N3D Unveils the Next Generation of 3D Cell Culturing System

Emirates PharmaAdvertisement

Only days after Rainbow BioSciences closed a deal to acquire an equity interest in Nano3D Biosciences, n3D announced the release of its groundbreaking new 24-well Bio-Assembler.

The new device is the latest iteration of n3D’s Bio-Assembler system, which promotes the development and growth of 3D cellular structures using magnetic levitation. Earlier Bio-Assembler models remain available in single-well and six-well platforms.

The 24-well system is a major milestone for the company, allowing much higher throughput productivity. With RBCC’s help, n3D plans to aggressively market the new device to large and busy laboratories around the world engaged in drug discovery, toxicology screenings, stem cell research and other research endeavors.

The Bio-Assembler’s revolutionary functionality allows it to produce accurate, 3D representations of in vivo tissues in roughly the same time needed to produce 2D cell cultures. It uses magnetic nanoparticles to levitate cells, allowing them to grow in three dimensions rather than flat on the bottom of a petri dish. The easy-to-use technology is compatible with any media, diagnostic technique or cell type.

N3D’s Bio-Assembler could be poised to forever alter the way cell culturing is conducted worldwide, with the potential to ultimately reduce the development timeline for new life-saving drug therapies. RBCC believes that its recent acquisition has the company well-positioned to participate in the potentially dramatic upside in store for n3D.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at www.RainbowBioSciences.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Emirates PharmaAdvertisement